Table 2 Baseline and 2-year follow-up medical data in the SLS and the control groups.
Continuous variables | SLS (n = 792) | P-value | Control (n = 3645) | P-value | ||
|---|---|---|---|---|---|---|
Baseline | 2-year | Baseline | 2-year | |||
Sex (male/female) | 559/233 | 3335/310 | ||||
Age | 53.87 ± 0.37 | 51.60 ± 0.13 | ||||
BW (kg) | 71.37 ± 0.51 | 69.62 ± 0.50 | <0.001*** | 73.02 ± 0.21 | 73.07 ± 0.21 | 0.487 |
BMI (kg/m2) | 25.83 ± 0.14 | 25.23 ± 0.15 | <0.001*** | 25.61 ± 0.06 | 25.66 ± 0.06 | 0.039* |
WC (cm) | 89.48 ± 0.35 | 88.03 ± 0.36 | <0.001*** | 88.67 ± 0.15 | 89.05 ± 0.16 | <0.001*** |
SBP (mmHg) | 126.22 ± 0.55 | 126.28 ± 0.62 | 0.922 | 127.82 ± 0.22 | 128.52 ± 0.27 | 0.009** |
DBP (mmHg) | 78.71 ± 0.41 | 78.17 ± 0.46 | 0.152 | 80.20 ± 0.16 | 80.70 ± 0.17 | 0.003** |
TG (mg/dl) | 143.05 ± 3.40 | 129.39 ± 3.79 | <0.001*** | 145.72 ± 1.77 | 145.47 ± 2.08 | 0.9 |
HDL-C (mg/dl) | 57.25 ± 0.55 | 59.02 ± 0.56 | <0.001*** | 56.94 ± 0.25 | 57.93 ± 0.26 | <0.001*** |
LDL-C (mg/dl) | 131.64 ± 1.16 | 126.10 ± 1.16 | <0.001*** | 127.06 ± 0.51 | 125.51 ± 0.59 | 0.004** |
FPG (mg/dl) | 107.46 ± 1.26 | 107.72 ± 1.03 | 0.843 | 111.86 ± 0.45 | 115.23 ± 0.48 | <0.001*** |
HbA1c (%) | 6.09 ± 0.03 | 6.05 ± 0.03 | 0.112 | 6.09 ± 0.01 | 6.21 ± 0.01 | <0.001*** |
AST (IU/l) | 25.77 ± 0.42 | 24.61 ± 0.53 | 0.029* | 25.42 ± 0.21 | 25.57 ± 0.31 | 0.607 |
ALT (IU/l) | 31.89 ± 0.83 | 27.57 ± 0.79 | <0.001*** | 31.99 ± 0.39 | 31.20 ± 0.43 | 0.052 |
γGTP (IU/l) | 48.15 ± 1.62 | 43.32 ± 1.68 | <0.001*** | 54.09 ± 0.89 | 54.48 ± 1.05 | 0.623 |
